Tag: BIO World Conference

AC Immune has entered into a second exclusive worldwide license agreement and research collaboration with Genentech,of the Roche Group, for the research, development and commercialization of AC Immune’s anti-Tau antibodies for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases. The agreement is valued at $400M.